Malignant Brenner Tumor: A Rare Tumor but Still Matters

Abstract

Introduction

Malignant Brenner tumor (MBT) is a rare epithelial ovarian neoplasm that has a poor prognosis and fewer than 1% prevalence in postmenopausal women. By examining the epidemiological, clinical, and follow-up information for three patients in a single tertiary care facility, we intended to add to the body of knowledge already accessible on this uncommon tumor type.

Method

This was a retrospective review involving three patients with MBT who had treatment at SRM Medical College and Research Institute in Tamil Nadu, South India, between the years 2020 and 2023.

Results

Our study participants are postmenopausal, with a mean age of 59.3 ± 11.1 years and a mean BMI of 27.1 kg/m². The tumor had solid and cystic regions and ranged in size from 5 to 20 cm. Two cases have been categorized as stage IA by FIGO 2014 and one as stage II A. The tumor in the current investigation was more prominent on the left side. Significant ascites were absent in any of the instances. Each of the three patients had a staging laparotomy. All three instances had Ca125 tests, and two of them had increased levels. The intraoperative results were almost in agreement with the imaging tests. In one case, surgery was followed by a six-month course of chemotherapy. Of the 3 patients, one had distant metastases and locoregional recurrence after 12 months. She died subsequently before receiving salvage treatment.

Conclusion

The diagnosis and ideal adjuvant management of MBT remains uncertain because of its rarity. Larger studies are required to confirm the favorable factors for a higher survival rate.